Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions by Batra, R.K. et al.
Retroviral Gene Transfer Is Inhibited by Chondroitin Sulfate
Proteoglycans/Glycosaminoglycans in Malignant Pleural Effusions*
(Received for publication, October 22, 1996, and in revised form, January 7, 1997)
Raj K. Batra‡, John C. Olsen, Diana K. Hoganson, Bruce Caterson§, and Richard C. Boucher
From the Division of Pulmonary Diseases, Department of Medicine, University of North Carolina, Chapel Hill,
North Carolina, and the §Connective Tissue Biology Laboratory, University of Wales, Cardiff, CF1 3US, United Kingdom
Gene therapy may be an important adjuvant for treat-
ing cancer in the pleural space. The initial results of
retroviral gene transfer to cancer cells in malignant
pleural effusions revealed that transduction was mark-
edly inhibited, and studies to characterize the inhibi-
tory factor(s) were performed. The inhibition was con-
tained within the soluble, rather than cellular,
components of the effusions and was demonstrated with
amphotropic, gibbon ape leukemia virus, and vesicular
stomatitis virus-glycoprotein pseudotyped retroviral
vectors. After excluding complement proteins, a series
of studies identified chondroitin sulfates (CSs) as the
inhibitory substances. First, treatment of the effusions
with mammmalian hyaluronidase or chondroitinases,
but not Streptomyces hyaluronidase, abolished the in-
hibitory activity. Second, addition of exogenous CS gly-
cosaminoglycans mimicked the inhibition observed
with pleural effusions. Third, immunoassays and bio-
chemical analyses of malignant pleural effusion speci-
mens revealed CS in relevant concentrations within
pleural fluid. Fourth, proteoglycans/glycosaminogly-
cans isolated from the effusions inhibited retroviral
gene transfer. Analyses of the mechanism of inhibition
indicate that the chondroitin sulfates interact with vec-
tor in solution rather than at the target cell surface.
These results suggest that drainage of the malignant
pleural effusion, and perhaps enzymatic pretreatment
of the pleural cavity, will be necessary for efficient ret-
roviral vector mediated gene delivery to pleural
metastases.
Malignant pleural effusions represent a terminal stage in a
disease process for which only symptomatic therapy exists (1,
2); therefore, new therapeutic strategies, including gene ther-
apy, appear warranted. We conducted a series of pilot experi-
ments that compared the transduction efficiencies of adenovi-
ral and retroviral vectors in various lung cancer subtypes and
determined that when indexed to multiplicity of infection (in-
fectious particles per cell), retroviral vectors are more efficient
than adenoviral vectors in transducing lung adenocarcinoma
cells (3). Because most malignant effusions from lung primar-
ies result from metastatic adenocarcinoma, we focused upon
retroviruses as the likely vector for this therapeutic indication.
Malignant effusions are often bloody due to neovasculariza-
tion and capillary leak associated with malignant cellular in-
filtration of the pleural surface. The fluid component of these
exudative effusions is often turbid and viscous, reflecting the
contributions of cellular debris and plasma proteins, as well as
secreted proteoglycans (PG),1 their glycosaminoglycan (GAG)
catabolites, and hyaluronic acid (2, 4, 5). Glycosaminoglycans
are long unbranched polysaccharide chains composed of repeat-
ing disaccharide units, linking an aminosugar (typically sul-
fated) with a uronic acid residue (in all cases except keratan
sulfate), which identifies the GAG chain as hyaluronic acid
(nonsulfated), chondroitin (or dermatan) sulfate, heparin, or
heparan sulfate. Except for hyaluronic acid, GAGs are found
associated with a core protein as proteoglycans (6, 7).
Preclinical studies testing gene transfer to primary cancer
cells in native malignant pleural effusions indicated that cells
in pleural fluid were poorly transduced by retroviral vectors
when compared with cells in media. Since the target cells in
these studies exhibited proliferation markers suggesting cell
replication (a requirement for retroviral transduction), the in-
hibition to transduction was suspected to be due to components
within the pleural fluid. To study the effect of pleural effusions
on the transduction efficiency of retroviral vectors in vitro,
target cell types that are highly transducible with amphotropic
retroviral vectors were used. This report provides the identifi-
cation of novel factors that inhibit retroviral transduction of
cells in pleural fluid, a finding that may have relevance to the
generally poor transduction efficiency observed in vivo using
retroviral vectors.
EXPERIMENTAL PROCEDURES
Cells—Mv1Lu cells, a mink lung epithelial cell line that is highly
permissive for gene transfer by amphotropic RV vectors (30–70% of the
cells are reproducibly transduced at multiplicities of infection of 1–5
(3)), were obtained from the ATCC and maintained in minimal essential
medium (Life Technologies, Inc.) supplemented with 10% fetal bovine
serum, nonessential amino acids, and penicillin (100 units/ml)/strepto-
mycin (100 mg/ml) (M10). H1437, a human lung adenocarcinoma cell line
derived from intrapleural metastases; H28, a human malignant me-
sothelioma cell line; and H226, a human lung squamous cell carcinoma
cell line derived from pleural metastases, were kind gifts from Dr.
Herbert Oie at NCI, National Institutes of Health (Bethesda, MD).
These cell lines were maintained in RPMI 1640 medium (Life Technol-
ogies, Inc.) supplemented with 10% fetal bovine serum and penicillin/
streptomycin (R10). CFT1 cells (8), a human bronchial epithelial cell line
that is efficiently transduced by gibbon ape leukemia virus (GALV) and
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amphotropic retroviral vectors (9), were maintained in defined serum-
free medium.
Pleural Effusions—Pleural effusions were harvested using aseptic
technique from patients with a known or suspected pleurally based
malignancy at the time of hospital admission. The effusion fluid used
for this study was in “excess” of the specimen required for diagnostic
purposes, and the experimental protocol was approved by the Univer-
sity of North Carolina Committee on the Protection of the Rights of
Human Subjects. All effusions studied exhibited exudative character-
istics, and the final diagnostic cytopathology suggested metastases from
the following primary cancers: non-small cell lung cancer (seven),
breast adenocarcinoma (three), ovarian cystadenocarcinoma (one), ma-
lignant thymic carcinoid (one), and parotid adenocarcinoma (one). The
remaining five effusions had suspicious but nondiagnostic cytopathol-
ogy, and data from these effusions were also included in the final
analyses.
Transduction studies using these effusions were generally performed
within 60 min of their removal from patients, with whole (unfraction-
ated) or effusion supernatants being used as vector diluents in trans-
duction efficiency assays (see below). The cellular debris was removed
from the effusions by centrifugation at 250 3 g for 15 min, and aliquots
of the supernatants stored at 270 °C were later used for detailed
characterization of the inhibitory factors. Complement was inactivated
by heating the effusions for 1 h at 60 °C, and all enzymatic treatments
of effusions were performed overnight at 37 °C on an orbital shaker at
200 rpm.
Vectors—All vectors used were based upon the Moloney murine leu-
kemia virus. LNPOZ (10) is a bicistronic retrovirus vector that uses a
poliovirus internal ribosome entry site sequence to express both the neo
and lacZ genes from a single mRNA. HIT-LZ2 is a lacZ-containing
vector with an immediate early CMV promoter/enhancer fused to the
retroviral R-U5 region in the 59-LTR (11). Amphotropic LNPOZ was
generated from the helper-free cell line PA-LNPOZ.1 (12). LNPOZ,
pseudotyped with the GALV envelope glycoproteins, was produced from
PG.LNPOZ.21, a clonal producer line derived from PG13 cells (13).
HIT-LZ, pseudotyped with the vesicular stomatitis virus (VSV) glyco-
protein, was transiently produced from 293 cells using the three-plas-
mid co-transfection system (11). Viral vectors were filtered through 0.2
mM cellulose acetate filters and stored at 270° until use. Prior to use,
virus stocks were tested for the passive transfer of b-galactosidase
(“pseudotransduction”) from virus producer cells (14) by analyzing cells
for lacZ expression immediately following infection. Under these con-
ditions, no b-galactosidase activity was detected in transduced cells.
Red Blood Cell (RBC) Isolation—Ten ml of whole blood were collected
in heparinized syringes from three healthy volunteers by venipuncture
on three separate occasions. The RBC mass was measured in an aliquot
of whole blood using a Coulter Counter (UNC Hospitals hematology
laboratories), and RBCs were isolated by Ficoll-Hypaque gradient sep-
aration (Sigma). Following isolation, RBCs were co-incubated with the
LNPOZ vector at hematocrits ranging from 0 to 15% for 30 min at 37 °C/
5% CO2, following which the RBCs were removed by centrifugation
(250 3 g) prior to vector delivery to target cells.
Retroviral Transduction Protocol and Analysis of Gene Transfer Ef-
ficiency—Cells were exposed to vector in 2 ml of vector containing
(transduction) media in 3.5-cm tissue culture wells (Costar). Unfrac-
tionated (whole) pleural effusions, effusion supernatants, or modified
effusion supernatant specimens (heated, enzymatically treated) were
mixed with 1 ml of the LNPOZ vector to constitute 1, 10, or 50% of a
final volume of 2 ml, with M10 and 8 mg/ml polybrene constituting the
remainder of the volume. The control transduction medium, used to
gauge the maximal achievable transduction in the absence of effusion
factors, was 1 ml of vector stock admixed with 1 ml of M10. Target cells
were transduced for 2 h at 37 °C and 5% CO2. Following this interval,
vector was aspirated, the cells were washed once with phosphate-
buffered saline, growth medium (M10) was added, the cells were incu-
bated at 37 °C in 5% CO2, and cells were harvested 48 h later for
transgene expression analyses.
Transduction efficiency of RV-transduced cells was quantified using
flow cytometry (FAC-Scan; Becton-Dickinson Immunocytometry Sys-
tems) by measuring intracellular FDG (Molecular Probes) hydrolysis.
Briefly, cells were detached from the tissue culture plates (1% trypsin,
1 mM EDTA), sedimented (250 3 g), and resuspended into 100 ml of
growth medium. Next, the cells were loaded with FDG during a brief
exposure to hypotonic shock (1 min at 37 °C in the presence of 1 mM
FDG in 1% Me2SO/H2O). FDG loading was terminated by the addition
of 400 ml of ice-cold M10 containing 1 mg/ml propidium iodide. The cells
were then placed on ice in the dark until fluorescence-activated cell
sorting analysis, in which 16,000 viable cells were evaluated for b-ga-
lactosidase expression. Nonviable cells, defined as the population that
had incorporated propidium iodide, were excluded in real time as red
fluorescent cells. Negative (cells that were not exposed to the vector but
were loaded with FDG) and positive (cells transduced in medium alone)
controls were included in all experiments. Cells displaying green fluo-
rescence exceeding the 99th percentile of the negative control popula-
tion constituted the transduced cell population.
The percentage of inhibition to transduction was calculated as (1 2
(% of transduction of the test cell population 2 % of transduction of the
negative control population)/(% of transduction of the positive control
cell population 2 % of transduction of the negative control population))
3 100. If the test cell population exhibited a transduction efficiency
greater than or equal to the positive control, the percentage of inhibi-
tion was reported as zero. Similarly, if the experimental population
exhibited a transduction efficiency less than or equal to the negative
control (i.e. #1%), the data were reported as 100% inhibition.
Alternatively, transduction efficiency of CFT1 cells by lacZ-express-
ing RV pseudotypes was quantitated by counting 200–400 cells follow-
ing histochemical staining with 5-bromo-4-chloro-3-indolyl b-D-galacto-
side (5 Prime 3 3 Prime, Inc., Boulder, CO) in three separate
experiments (15).
PG/GAG Protocols—Hyaluronic acid, chondroitin sulfate A (also re-
ferred to as CSA and chondroitin 4-sulfate), and chondroitin sulfate B
(also referred to as dermatan sulfate) were derived from bovine tracheal
mucosa (Sigma). Chondroitin sulfate C (also referred to as chondroitin
6-sulfate) was derived from shark cartilage (Sigma Biochemical). Each
glycosaminoglycan was reconstituted in phosphate-buffered saline (1
mg/ml), and transduction efficiency was measured following exposure of
vector admixed with GAG at varying concentrations. In separate ex-
periments, glycosaminoglycans (100 mg/ml) were preexposed to target
cells for 2 h and aspirated off before LNPOZ infection.
Enzyme Protocols—The concentration and conditions for the enzy-
matic digestion of pleural fluid were modifications of procedures used
for the isolation of PG/GAG from synovial fluid, vitreous humor, and
cartilage (16–22). Excessive amounts of all enzymes were utilized be-
cause their relative activities in biological fluids is unknown. Bovine
testicular hyaluronidase (BTH), a mammalian hyaluronidase (Sigma),
and Streptomyces hyaluronidase (S-Hya), a bacterial hyaluronidase
(Seikagaku Amano Pharmaceutical Company, Rockville, MD), were
reconstituted in 50 mM sodium acetate, pH 6.0. Chondroitinase AC
(Flavobacterium heparinum), and chondroitinase ABC (CABC) (P. vul-
garis) were acquired from Sigma and reconstituted in 50 mM sodium
acetate/phosphate-buffered saline, pH 7.4. Heparinase (F. heparinum),
heparitinase (F. heparinum), and keratanase (Pseudomonas sp.) were
purchased as lyophilized preparations from Seikagaku and reconsti-
tuted in 50 mM sodium acetate/phosphate-buffered saline, pH 7.4.
Enzymatic treatments of pleural fluid were performed overnight at
37 °C, and retroviral transduction of target cells in the presence of
treated or untreated effusions was compared. To evaluate the effect of
BTH treatment on cell transduction, a variety of cell types were pre-
treated with various concentrations of BTH at 37 °C for 4 h prior to RV
exposure.
Protocols for the Isolation and Identification of PG/GAG in Pleural
Fluid—PG/GAG were purified from 10 ml of six effusion supernatants
(representing a range of inhibition to retroviral transduction) by ultra-
centrifugation (100,000 3 g for 48 h) in a dissociative (4 M guanidine
HCl) CsCl density gradient. Following ultracentrifugation, the tubes
were snap frozen at 280 °C and cut into three equal aliquots. The
recovered fractions possessed mean specific densities of 1.6 g/ml (bot-
tom fraction, D1), 1.45 g/ml (middle fraction, D2), and 1.34 g/ml (top
fraction, D3). These fractions were dialyzed (molecular weight cut-off of
3500) against distilled, deionized water at 4 °C for 2 days (five exchang-
es). Following dialysis, the fractions were lyophilized, and the PG/GAGs
in each fraction were resolubilized in 10 ml of water. The uronic acid
content in each fraction was quantitated by the modified carbazole
method (23, 24), and the sulfated GAG concentration was measured by
the dimethylmethylene blue (DMMB) assay (25). Estimates of the total
hexuronic acid and sulfated GAG content in the effusions were made by
adding the PG/GAGs isolated in the D1 and D2 fractions derived from
each effusion.
Next, the reconstituted D1 and D2 fractions were evaluated for their
effect on RV transduction by infecting target cells with LNPOZ in the
presence of the isolated PG/GAG. In addition, the D1 fractions isolated
from each of three effusions were treated with a panel of enzymes that
degrade an array of PG/GAGs to determine whether any of the observed2 J. C. Olsen, unpublished observations.
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inhibition could be abolished by this procedure.
To size-fractionate the chondroitin PG/GAGs in malignant pleural
effusions, 2-ml aliquots of Streptomyces hyaluronidase-treated effu-
sions were gel-filtered through a 20-ml Sepharose CL-6B column (Phar-
macia Biotech Inc.) equilibrated with 4 M guanidine HCl. Two-ml frac-
tions were collected using 4 M guanidine HCl, 50 mM Tris, and fractions
containing chondroitin sulfates were identified with a dot blot immu-
noassay (see below). The void volume was determined by chromatogra-
phy of blue dextran (approximately 2 million daltons; Fluka, New
York), and the bed volume (salt peak) was determined by chromatog-
raphy of the bromphenol blue dye (approximately 700 daltons; Sigma)
from the column.
Identification of PGs in pleural effusions was carried out by immu-
noassay utilizing murine monoclonal antibodies with specificity for
CSA, chondroitin 6-sulfate, or sulfated GAGs. The 2B6 monoclonal IgG
antibody specifically detects nonreducing D-unsaturated disaccharides
of CSA, and the 3B3 monoclonal IgM antibody reacts with a nonreduc-
ing D-unsaturated disaccharides in chondroitin 6-sulfate (16, 26) fol-
lowing chondroitinase treatment, which exposes the specific residues in
native PGs. The 7D4 monoclonal IgM antibody recognizes a sequence of
isomers with different sulfation patterns in native chondroitin sulfate
(18). For these analyses, 100-ml aliquots of effusion supernatants, seri-
ally diluted in 50 mM Tris-HCl, 200 mM NaCl, 0.02% NaN3 (Tris-salt
buffer, pH 7.0), were loaded onto nitrocellulose membranes (0.2-mm
pore; Schleicher and Schuell, Keene, NH) using a dot blot apparatus
(Bio-Rad) at room temperature. The membranes were blocked using 5%
BSA in Tris-salt buffer for 2 h, treated with chondroitinase ABC (0.01
units in 0.1 M Tris acetate, pH 8, for 1 h) to expose the epitopes for
immunoassays using the 2B6 and 3B3 primary antibodies, washed with
Tris-salt buffer, and incubated for 1 h with the primary antibody (1:
1000 in 1% BSA). The 7D4 immunodetection was performed on native
proteoglycans without chondroitinase treatment. Membranes were
washed three times with Tris-salt buffer and incubated with the sec-
ondary antibody (1:7500 in 1% BSA, anti-mouse IgG conjugated to
alkaline phosphatase (AP)) (Promega, Madison, WI) for 1 h. After three
additional washes, the dot blots were exposed to AP substrate (Pro-
mega) for 15 min and analyzed colorimetrically. Bovine nasal cartilage
core was used as the positive control for detection of chondroitin sulfate
proteoglycan (2B6 and 3B3 antibodies), and aggrecan from shark car-
tilage was used as the positive control for detection of sulfated GAG
(7D4 antibody).
Statistics—Data are reported as means 6 S.E. with the overall
statistical significance of differences within the groups determined us-
ing one-way analysis of variance. Kruskal-Wallis analysis of variance is
initially performed on ranks, followed by the Student-Newman-Keuls or
Bonferroni group comparisons. For Figs. 2 and 3, the statistical signif-
icance of the difference between the treated versus untreated groups
was calculated using the two-tailed paired t test. For all statistical
analyses, p , 0.05 was considered significant.
RESULTS
Inhibition of Retroviral Gene Transfer to Target Cells in
Malignant Pleural Effusions—Unfractionated (whole) pleural
effusions harvested from patients with suspected intrapleural
malignancies inhibited retroviral transduction of Mv1Lu cells
in a dose-dependent manner (Fig. 1A). An approximate 75%
inhibition of amphotropic retroviral transduction was observed
when these effusions were admixed 1:1 with the retroviral
vector-containing medium (Fig. 1A). These initial observations
suggest that there are factors inhibitory to amphotropic retro-
viral transduction contained within malignant pleural effu-
sions and led first to studies to discriminate between the cel-
lular versus soluble components as mediators of this effect.
We postulated that the amphotropic retroviral receptor
(RAM-1) (27) may be expressed in the RBC plasma membrane
and bind the LNPOZ vector prior to its interaction with the
target cell. However, when RBCs were coincubated with retro-
viral vectors in the range of hematocrits typically present in
malignant pleural effusions (0–1.5%), only a small inhibition of
transduction was detected (Fig. 1B). At a hematocrit of 15%
(RBC content one-third that present in blood), a 50% reduction
in transduction efficiency was seen. Because RBC concentra-
tions representing the maximal hematocrit in malignant pleu-
ral effusions (;1.5%) could only account for a small component
(,20%) of the overall inhibition exhibited by whole effusions,
other factors are responsible for the majority of the inhibition
to retroviral transduction.
We next tested whether soluble factors within the effusions
were blocking retroviral transduction. To test this hypothesis,
cells and particulate debris were removed by centrifugation,
and the effusion supernatants were evaluated in transduction
efficiency assays. Fig. 1C shows a dose-dependent inhibition to
retroviral transduction by the effusion supernatants in a pat-
tern that is virtually identical to that observed with whole
effusions (Fig. 1A). This observation suggests that the inhibi-
tion to retroviral transduction by malignant effusions is medi-
ated by soluble factors present in the fluid component of those
effusions.
To investigate whether this finding was relevant to target
cells other than Mv1Lu and to other candidate retroviral vec-
tors, the inhibition to transduction in the presence of effusion
supernatant was tested for and observed when the human lung
adenocarcinoma cell line H1437 (68 6 13.4% inhibition) was
used as the target cell type. Next, using the human bronchial
FIG. 1. Comparison of the inhibition of amphotropic retroviral
transduction efficiency in the presence of whole (unfraction-
ated) pleural effusions (A), RBCs (B), and supernatants (C) frac-
tionated from whole pleural effusions. Mv1Lu cells were trans-
duced with the LNPOZ amphotropic retroviral vector in the presence or
absence (control) of freshly harvested malignant pleural effusions (n 5
5), RBCs (n 5 9, three separate experiments using RBCs from three
subjects), or effusion supernatants (n 5 16). The efficiency of reporter
lacZ gene expression was quantified as the percentage of cells trans-
duced by flow cytometry. Shown is the inhibition to transduction (com-
pared with control) by the vector in the presence of increasing volume
percentages of the effusions or hematocrits in LNPOZ-containing me-
dium. Data are presented as means 6 S.E. *, p , 0.05; **, p , 0.001, for
a statistically significant difference from control by the Student-New-
man-Keuls pairwise multiple comparison analysis.
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epithelial cell line (CFT1) as the target cells, transduction
efficiencies of amphotropic, VSV-G, and GALV pseudotyped
vectors were tested in the presence or absence of effusion su-
pernatants. In the presence of effusions, amphotropic RV (LN-
POZ) transduction is inhibited over a broad range of ampho-
tropic vector concentration (Fig. 2A). Furthermore, as
demonstrated in Fig. 2, B and C, the inhibition of RV trans-
duction extends to the VSV-G and GALV pseudotyped vectors
as well.
Inactivation of Complement and Identification of the Inhibi-
tory Factors Using Differential Enzymatic Digestion and the
Addition of Exogenous GAGs—Because recent reports have
attributed the reduced RV transduction into target cells in the
presence of human serum to complement-induced lysis of the
retroviral vector (28, 29), we first tested whether the observed
inhibition to retroviral transduction was complement-depend-
ent. Complement levels within the malignant pleural effusions
were measured (C3 and C4 measured by rate nephelometry,
and CH50 levels measured by complement-mediated sheep
RBC lysis; UNC Hospital Labs) and did not correlate with the
observed inhibition (data not shown). Furthermore, heating the
effusions to inactivate complement components did not remove
the block to transduction (Fig. 3).
Malignant pleural effusions are often highly turbid and vis-
cous, reflecting in part the contribution of secreted PG/GAG. To
test an alternative hypothesis that proteoglycans block retro-
viral transduction, pleural effusion supernatants were treated
with BTH, a mammalian enzyme with a broad activity against
PG/GAGs (7, 21). A marked reduction in the inhibitory activity
of the effusions was observed following BTH treatment (Fig. 3),
implicating either hyaluronic acid or other PG/GAGs as the
putative factors mediating the inhibition to retroviral
transduction.
A series of experiments were next performed to specifically
identify the inhibitory glycoconjugates. First, effusions were
pretreated with a more specific hyaluronidase derived from
Streptomyces (S-Hya) (30, 31) to test whether hyaluronic acid
was responsible for the observed inhibition. As shown in Fig. 4,
S-Hya, at a range of effective concentrations (19, 22), did not
affect the block to transduction, whereas the inhibitory factors
within these effusions were still susceptible to BTH activity.
The differential susceptibility of the inhibitory factor(s) to the
mammalian BTH versus the bacterial S-Hya demonstrated
that hyaluronic acid was not the component responsible for
mediating the inhibition to retroviral transduction.
Based on data indicating that BTH cleaves chondroitin (and
dermatan) sulfates in addition to hyaluronic acid (7), we tested
whether the inhibitory factor(s) was a member of the chon-
droitin sulfate family of PG/GAGs by treating effusion super-
natants with specific chondroitinases (20, 26). Pretreatment of
effusions with chondroitinase AC or ABC was as effective as
BTH (Fig. 5) in abolishing the inhibition of transduction with
retroviral vectors, suggesting that chondroitin sulfates are the
components inhibiting retroviral transduction in pleural
effusions.
To verify the identity of the glycoconjugates responsible for
inhibiting retroviral transduction, BTH-degradable glycosami-
FIG. 2. CFT1 transduction in the presence or absence of effu-
sions over a range of amphotropic RV vector concentration (A)
or using VSV-G (B) or GALV (C) pseudotyped retroviral vectors.
CFT1 cells were transduced with various vectors admixed (50%, v/v)
with effusion supernatants or medium. 48 h after transduction, the
efficiency of gene transfer was quantitated using the 5-bromo-4-chloro-
3-indolyl b-D-galactoside histochemical assay and by microscopically
counting the percentage of blue cells. Each data point in A represents
the mean transduction efficiency of two groups of cells in the absence
(M) or presence (E, Ç) of two different effusions. B and C show the
mean 6 S.E. transduction efficiency of three groups of cells exposed to
the VSV-G or GALV pseudotyped vectors in the absence (C) or presence
(E) of effusions. *, a statistically significant (p , 0.01) difference be-
tween the groups by a paired t test analysis.
FIG. 3. Comparison of the inhibition of amphotropic retroviral
transduction by untreated pleural effusion supernatants, su-
pernatants heated (60 °C for 1 h) to inactivate complement, or
supernatants treated with bovine testicular hyaluronidase (250
units/ml BTH). Shown is the inhibition to transduction of Mv1Lu cells
by the LNPOZ amphotropic retroviral vector admixed (50%, v/v) with
untreated effusion supernatants, heated effusion supernatants, or ef-
fusion supernatants treated with BTH. The reporter lacZ gene expres-
sion is quantified by flow cytometry. n 5 16 for each group, data
presented as means 6 S.E., *, the two-tailed p value from a paired t test
analysis where p , 0.001 for a statistically significant difference be-
tween the untreated and BTH-treated group.
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noglycans were added into the vector supernatants at varying
concentrations (Fig. 6). Hyaluronic acid did not inhibit retrovi-
ral transduction, whereas inhibition to transduction was ob-
served when CSA, chondroitin 6-sulfate, or dermatan sulfate
was added into retroviral stock at various concentrations. Am-
photropic retroviral transduction was virtually abolished when
concentrations of the sulfated GAGs exceeded 50 mg/ml in the
LNPOZ-containing medium.
Immunodetection and Quantitative Biochemical Analysis of
Chondroitin Sulfates in Malignant Pleural Effusions—We next
tested whether the chondroitin sulfates identified as the inhib-
itory factors (Figs. 5 and 6) were present in pleural fluid. First,
randomly selected effusion specimens were tested for the pres-
ence of sulfated GAGs, chondroitin 4-sulfate, and chondroitin
6-sulfate, using immunoassays. As shown in Fig. 7, the target
proteoglycan epitopes were detected in every effusion tested at
serial dilution of the effusions to 1:50,000, indicating that chon-
droitin sulfate proteoglycans are components of malignant
pleural effusions. Gel filtration (Sepharose CL-6B) analysis of
effusions showed that the CS moieties started eluting with the
void volume and continued to elute until the salt peak was
reached (data not shown), suggesting that chondroitin sulfates
in malignant pleural effusions are a heterogeneous group rep-
resented by elements with molecular masses of over 1 million
to smaller fragments of less than 10,000 daltons.
Hexuronic acid and total glycosaminoglycan sulfation con-
tent were used as markers in biochemical assays to test
whether relevant concentrations of GAGs were present within
pleural effusions. For these studies, PG/GAGs were purified
directly from representative (moderately to completely inhibi-
tory to retroviral transduction) effusion supernatants. The hex-
uronic acid concentrations in the D1 and D2 fractions of the
CsCl density gradient-purified effusions ranged from 6.6 to
58.4 mg/ml (mean 6 S.E. 5 27.37 6 8.69 mg/ml). Assuming that
40% of the isolated PG/GAGs is hexuronic acid (23, 24), the
mean PG/GAGs concentration in the effusions was estimated to
be 68 mg/ml. Similarly, the mean 6 S.E. sulfated GAG concen-
tration in the effusions was determined to be 30 6 7.9 mg/ml.
These concentrations of uronic acid and sulfated PG in the
effusions fall within the range predicted to be inhibitory
(Fig. 6).
Transduction Bioassays Using PG/GAG Isolated from Effu-
sions—Following their purification by CsCl density gradient
centrifugation from pleural effusions, the PG/GAGs were
tested in bioassays measuring inhibition to retroviral transduc-
tion and found to be inhibitory (Fig. 8). For example, the in-
hibitory activity of the D1 fraction from three representative
effusions mirrored the inhibition by the effusion supernatant
and responded to enzymatic treatment with BTH or chondroiti-
nases in an analogous manner. In contrast, heparinase, hep-
aritinase, keratanase, and Streptomyces hyaluronidase had no
impact upon the observed inhibition, indicating that heparin,
heparan sulfates, keratan sulfate, and hyaluronic acid are not
the inhibitory substances in this milieu and that chondroitin
sulfates are the relevant inhibitory factors in malignant pleu-
ral effusions (Fig. 8).
Mechanism(s) of Inhibition of Retroviral Transduction by
CS—Finally, we investigated the mechanism(s) of action for
the PG/GAG-mediated vector inhibition. By incrementally in-
creasing the polybrene concentrations in the vector/effusion
admixtures up to 40 mg/ml (a 5-fold excess), only about 25% of
the effusion-mediated inhibition could be reversed (data not
FIG. 4. Comparison of the inhibition of amphotropic retroviral
transduction in the presence of untreated effusion superna-
tants or in the presence of effusion supernatants treated with
the mammalian BTH or the bacterial S-Hya. Mv1Lu cells were
transduced with the LNPOZ amphotropic retroviral vector in the pres-
ence (50%, v/v) of four effusion supernatants treated with BTH or S-Hya
at equivalent unit concentrations, and the reporter lacZ gene expres-
sion was quantified. n 5 4 effusion specimens, data presented as
means 6 S.E. *, p , 0.05 for a statistically significant difference from
control by the Bonferroni pairwise multiple comparison analysis.
FIG. 5. Inhibition of amphotropic
retroviral transduction in the pres-
ence (50%, v/v) of untreated effusion
supernatants (U) compared with ef-
fusion supernatants treated with
varying concentrations of chon-
droitinase AC (CAC), chondroitinase
ABC (CABC), or BTH. Mv1Lu cells were
transduced with the LNPOZ amphotropic
retroviral vector in the presence (50%,
v/v) of five separate effusion supernatants
or of the same effusion supernatants
treated with chondroitinase AC or CABC
or BTH. The reporter lacZ gene expres-
sion is quantified as the percentage of
cells transduced by flow cytometry.
Shown is the relative inhibition to trans-
duction by the vector in the presence of
untreated versus treated effusion super-
natants in LNPOZ-containing medium.
n 5 5 effusion specimens. Data are pre-
sented as means 6 S.E. *, p , 0.05 for a
statistically significant difference from
control by the Bonferroni pairwise multi-
ple comparison analysis.
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shown). This finding suggested that the anionic nature of the
PG/GAG is probably playing a minor role in the vector/proteo-
glycan interaction. To test whether mammalian hyaluronidase
cleaves PG/GAGs associated with the target cell surface rather
than in pleural fluid, Mv1Lu or the human tumor cell lines
H226 and H28 were treated with various concentrations of
BTH over a 4-h period, washed free of BTH, and then exposed
to the LNPOZ vector. Fig. 9 shows that BTH pretreatment of
cells does not effect transduction efficiency into cells. In a
second series of experiments to test whether PG/GAGs coat the
target cell surface and block retroviral attachment, we prein-
cubated target cells for 2 h with effusion supernatants or ex-
ogenous glycosaminoglycans at a concentration of 100 mg/ml,
and aspirated these components prior to vector exposure. In
this analysis, the inhibition to the transduction efficiency into
cells preincubated with hyaluronic acid, CSA, dermatan sul-
fate, chondroitin sulfate C, or patient effusions was small
(ranging from 1 6 1.2% (CSA) to 19.9 6 12.7% (mean 6 S.E. of
five different effusions)) and not statistically different from the
transduction efficiency of control cells that were not preincu-
bated with PG/GAGs or effusions. Taken together, these re-
sults suggest that the mechanism of action of CS inhibition is
not at the target cell surface, but rather in solution to inhibit
RV gene transfer.
DISCUSSION
During preclinical evaluation of a gene therapy strategy for
malignant pleural disease using retroviral vectors, we observed
that the transduction efficiency of amphotropic retroviral vec-
tors was markedly impaired or completely nullified in the pres-
ence of malignant pleural effusions (Fig. 1A). This inhibition to
transduction constitutes a significant barrier to the therapeutic
goal, and consequently, we sought to identify and neutralize
the inhibitory factors in the pleural effusions responsible for
this effect.
Initially, we investigated whether the inhibitory factors were
contained within the cellular or soluble components of the
pleural effusion. We found minimal inhibition attributable to
RBCs when present in the range of hematocrits present in
pleural effusions (Fig. 1B); however, our analysis predicts that
RBCs (or serum factors that co-sedimented with the red cells in
a Ficoll-Hypaque gradient) would be inhibitory to retroviral
transduction when present at a volume percentage found in
blood. Since the RBC-mediated block to retroviral transduction
FIG. 6. Inhibition of amphotropic retroviral transduction in
the presence of exogenous glycosaminoglycans (GAG; mg/ml)
admixed with vector containing medium. Mv1Lu cells were trans-
duced with the LNPOZ amphotropic retroviral vector in the presence of
hyaluronic acid (f), chondroitin sulfate A (●), chondroitin sulfate B (å),
or chondroitin sulfate C (,) at concentrations ranging from 0 to 100
mg/ml GAG. The reporter lacZ gene expression is quantified as the
percentage of cells transduced by flow cytometry. Shown is the relative
inhibition of retroviral transduction (compared with control) as a func-
tion of increasing concentrations of exogenous GAGs in LNPOZ-con-
taining medium (n 5 3 separate experiments; data are presented as
means 6 S.E.).
FIG. 7. Dot blot immunoassays testing for the presence of
chondroitin 4-sulfate (using the 2B6 antibody), chondroitin
6-sulfate (using the 3B3 antibody), and native chondroitin sul-
fate epitopes (using the 7D4 antibody) in malignant pleural
effusion supernatants. 100 ml of seven (1–7) serially diluted effusion
specimens (1:1000, 1:5000, 1:10,000, and 1:50,000 in Tris-salt buffer)
were assayed for the presence of chondroitin 4-sulfate and chondroitin
6-sulfate using bovine nasal cartilage core (at concentrations of 50, 10,
5, and 1 ng/ml) as the control (C) antigen. For these analyses, samples
were applied to the nitrocellulose, blocked, then pretreated with chon-
droitinase ABC to generate epitopes recognized by antibodies 2-B-6 and
3-B-3 (16, 17, 47). Similarly, 100 ml of six serially diluted effusion
specimens (1:1000, 1:2500, 1:10,000, and 1:25,000) were assayed for the
presence of native chondroitin sulfate epitope (7D4 antibody) without
chondroitinase pretreatment and using digested shark cartilage (50, 10,
5, and 1 ng/ml) as the control (C) epitope. The primary murine antibod-
ies (diluted 1:1000 in 1% BSA) were recognized by a secondary (diluted
1:7500 in 1% BSA) anti-mouse IgG conjugated to AP and detected
following exposure to the AP substrate.
FIG. 8. Comparison of the inhibition of amphotropic retroviral
transduction by untreated effusion supernatants, PG/GAGs iso-
lated from effusions, or PG/GAGs isolated from the effusions
that have been enzymatically treated with a variety of specific
enzymes. Shown is the relative inhibition to transduction conferred by
supernatants from three malignant effusions, the PG/GAGs isolated
with the D1 fraction (specific gravity 1.6 g/ml) from those effusions, or
the PG/GAGs isolated with the D1 fraction that have been treated with
a panel of specific degradative enzymes. A, 50% (v/v with LNPOZ vector
stock) effusion supernatant; B, 50% D1 fraction; C, 50% D1 fraction plus
Streptomyces hyaluronidase (10 units/ml); D, 50% D1 fraction plus
bovine testicular hyaluronidase (250 units/ml); E, 50% D1 fraction plus
chondroitinase AC (0.5 units/ml); F, D1 fraction plus chondroitinase
ABC (0.5 units/ml); G, 50% D1 fraction plus heparinase (5 units/ml); H,
50% D1 fraction plus heparitinase (5 units/ml); I, 50% D1 fraction plus
keratanase (1 unit/ml). n 5 3 effusion specimens; data are presented as
means 6 S.E. *, p , 0.001 for a statistically significant difference from
control by the Student-Newman-Keuls pairwise multiple comparison
analysis.
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did not appear to be relevant in the context of malignant
pleural effusions, the affinity (receptor) of the RBCs for vector
and the reversibility of this interaction were not further
studied.
Next, we determined that the inhibition to retroviral trans-
duction observed in whole unfractionated effusions was repro-
duced by the acellular (supernatant) component of the effu-
sions (Fig. 1C). In fact, as demonstrated in Fig. 2, the inhibition
was present over a broad range of the amphotropic RV-vector
concentrations and was observed using other (VSV-G, GALV)
RV pseudotypes with potential applications for gene therapy.
These data suggest that soluble factors within the milieu of
malignant pleural effusions adversely affect retroviral trans-
duction in a generic manner. Inactivation of complement pro-
teins, known mediators of retrovirolysis (32), did not signifi-
cantly affect the inhibition to retroviral transduction (Fig. 3);
however, treatment with a mammalian hyaluronidase (BTH) to
degrade PG/GAGs, markedly reduced the inhibitory activity of
the effusions (Fig. 3). The elimination of the inhibitory activity
with enzymatic pretreatment by BTH suggested that hyalu-
ronic acid and/or chondroitin sulfates were the PG/GAGs re-
sponsible for the inhibitory effect. To distinguish between these
possibilities, a series of studies were performed. First, effusions
treated with a more specific bacterial hyaluronidase (S-Hya)
maintained their inhibitory activity, suggesting that hyalu-
ronic acid was an unlikely candidate for mediating this effect
(Fig. 4). This inference was supported by the observation that
the addition of exogenous hyaluronic acid (up to 500 mg/ml;
data not shown) had no effect upon the transduction efficiency
of retroviral vectors (Fig. 6). In contrast, the inhibitory activity
in effusions was abolished by specific chondroitinases (Fig. 5),
and inhibition to retroviral transduction was detected when
exogenous CS glycosaminoglycans were added to the ampho-
tropic RV vector (Fig. 6). These data indicate that chondroitin
sulfates in malignant pleural effusions are the likely inhibitors
of retroviral gene transfer.
To demonstrate the relevant molecules in vivo, pleural effu-
sions were assayed for the presence of chondroitin sulfate moi-
eties by biochemical and immunodetection techniques (Fig. 7).
The immunoassays confirmed the presence of the relevant PG/
GAGs in pleural fluid, and quantitatitive biochemical assays
revealed them to be in the range of concentrations predicted to
be inhibitory from previous studies (Fig. 6). In addition, the
purified PG/GAGs isolated from the pleural effusions were
found to inhibit retroviral transduction in a manner identical
to that of whole effusions, and this inhibitory activity could be
eradicated by enzymatic treatment with BTH or chondroiti-
nases (Fig. 8). Importantly, enzymatic treatment of the frac-
tions with heparinase, heparitinase, and keratanase had no
effect on the inhibitory capacity of these isolates. Collectively,
the results of biochemical, immunodetection, and differential
enzymatic digestion analyses conclusively demonstrate that
the inhibition to retroviral transduction in the pleural fluid can
be accounted for by the activity of chondroitin sulfates in the
effusion.
Although it is not possible to test directly, our data suggest
that the PG/GAGs block RV transduction by binding or inacti-
vating the vector in solution rather than adsorbing onto the cell
surface. No effect upon transduction efficiency was observed
when three cell lines were pretreated with various concentra-
tions of BTH before infection with retroviral vector (Fig. 9), and
preincubation of the target cells with exogenous GAG did not
impair subsequent retroviral transduction, provided that the
GAGs were aspirated from the cells prior to vector exposure.
The proteoglycan families (and their glycosaminoglycan ca-
tabolites) in malignant pleural effusions have not been exten-
sively studied to date. Elevated concentrations of hyaluronic
acid are known to be present in effusions from patients with
malignant mesothelioma (33), and more recently, these GAGs
have been characterized to include both hyaluronic acid and
sulfated moieties (5). In addition, mesothelial cells have been
recognized as a source of secreted hyaluronic acid and chon-
droitin GAG (34, 35). In this regard, the majority of sulfated
GAGs produced by rat mesothelial cells in vitro are shown to be
secreted into the media, and only 25% of the sulfated GAG is
cell surface- or extracellular matrix-related. Elevated quanti-
ties of PG/GAGs have also been measured in tumor tissue and
in pleural effusions of patients with inflammatory conditions
(36). Our results suggest that the relevant molecules inhibitory
to RV-transduction in malignant pleural effusions likely origi-
nate from parent proteoglycans that are secreted and have CS
components (e.g. versican, and/or members of the biglycan or
decorin families) (37). Furthermore, the source of these parent
proteoglycans may be the mesothelial cell (34, 35) or tumor
stroma per se (38).
PG/GAGs play diverse roles in different tissues, and their
important interaction with certain infectious agents is increas-
ingly being appreciated (39–41). For example, the cell surface
heparan GAGs are the site for the initial viral attachment of
herpesvirus, pseudorabies virus, and cytomegalovirus onto the
cell surface (40, 42, 43). Likewise, several sulfated polysaccha-
rides are potent and selective inhibitors of infection due to
various enveloped viruses, including vesicular stomatitis virus
(VSV, a rhabdovirus) and human immunodeficiency virus
(HIV, a lentivirus) (44). Indeed, dextran sulfate and heparin
(but not chondroitin sulfates) prevent HIV replication and syn-
cytia formation in vitro (45, 46). In this report, we demonstrate
that a variety of enveloped (amphotropic, GALV, VSV-G) RV
vectors are inhibited from transducing target cells by soluble
chondroitin sulfates. These results are compatible with prior
observations and expand the role for connective tissue glyco-
conjugates in their interactions with infectious agents and
potential vectors for gene therapy.
The mechanism(s) by which vector inactivation is taking
place remains to be resolved. The interaction of the glycocon-
jugates with the viral vector may be a steric phenomenon or in
FIG. 9. Transduction efficiency of LNPOZ into three cell lines
(H28 (human malignant mesothelioma, f), H226 (human lung
squamous cell carcinoma, ●), and Mv1Lu (mink lung epithe-
lium, å)) pretreated in culture with BTH (units/ml in mainte-
nance medium). Cells were transduced with the LNPOZ amphotropic
retroviral vector following pretreatment of the cells with BTH and
analyzed for lacZ expression by flow cytometry. (Each data point rep-
resents the mean efficiency of transduction from two measurements).
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part a function of the polyanionic charge of the PG/GAGs.
However, a more specific relationship is perhaps suggested by
affinity of herpesvirus and cytomegalovirus only for cell-asso-
ciated heparan sulfates and the inability of chondroitin sulfates
to affect HIV infection. The implications of our findings for gene
therapy of intrapleural malignancy are clear if amphotropic RV
vectors are utilized in that vector neutralization by soluble
PG/GAGs would likely occur in a pleural cavity containing an
effusion. However, potential strategies to overcome this effu-
sion-mediated inhibition to RV transduction are suggested by
our study. Most simply, the effusion accompanying the pleural
process should be drained completely to remove soluble proteo-
glycans/glycosaminoglycans from the chest cavity before the
instillation of vector. In addition, pretreatment of the pleural
cavity with mammalian hyaluronidase or specific chondroiti-
nases may enhance retroviral gene transfer to the target cells
in vivo.
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